OncoTherapy Science (4564) AI Stock Analysis

2 Followers

OncoTherapy Science

(TSE/TYO:4564)

Select Model

Rating:42Neutral

Price Target:JPY 16.50▼(-2.94% Downside)

Action:reiterated

Date:08/11/26

The low overall score of 42 is heavily influenced by the firm's lack of profitability, severe cash burn, and bearish technical setup. While the exceptional, debt-free balance sheet provides critical operational runway, the negative valuation metrics and downward price trends underscore the high-risk nature of this investment.

Positive Factors

Zero debt and stronger equity cushionThe absence of reported debt reduces interest burden and refinancing exposure, while the increase in equity provides a stronger capital cushion. This gives OncoTherapy Science more flexibility to continue oncology research and manage volatility, although ongoing losses could erode that protection over time.

Negative Factors

Volatile and declining revenueRecent revenue contraction and historical volatility make the commercial trajectory difficult to predict and weaken the foundation for operating leverage. Without more consistent growth from oncology candidates or related technologies, fixed research costs are harder to absorb and recovery may take longer.

OncoTherapy Science (4564) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 6.94B
Dividend Yield: ―
Average Volume (3M): 186.01M
Price to Earnings (P/E): -7.2
Beta (1Y): 1.03
Revenue Growth: -8.58%
EPS Growth: 19.03%
Country: Japan
Employees: 46
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

OncoTherapy Science Business Overview & Revenue Model

Company Description

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound th...

How the Company Makes Money

The company’s monetization is generally tied to commercializing oncology drug candidates and related technologies through development and partnering, including potential revenue from licensing/out-licensing, collaborative research arrangements, and m...

OncoTherapy Science Financial Statement Overview

Summary

The company displays the high-risk profile of an early-stage biotech firm, characterized by heavy cash burn and massive operational losses. However, this is partially mitigated by a pristine, debt-free balance sheet that provides essential financial runway.

Income Statement

25Negative

Balance Sheet

82Very Positive

Cash Flow

20Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2022	Mar 2021
Income Statement
Total Revenue	749.75M	808.53M	750.05M	610.12M	1.13B	332.48M
Gross Profit	-12.76M	13.96M	-12.76M	-177.72M	41.69M	19.54M
EBITDA	-126.67M	-810.38M	-14.92M	-165.50M	-1.10B	-1.59B
Net Income	-815.05M	-910.64M	-815.28M	-1.29B	-1.12B	-1.56B
Balance Sheet
Total Assets	1.16B	2.36B	1.16B	867.27M	1.51B	3.37B
Cash, Cash Equivalents and Short-Term Investments	833.88M	2.09B	833.88M	527.66M	1.12B	2.90B
Total Debt	51.07M	0	51.07M	106.85M	0	0
Total Liabilities	426.09M	217.37M	426.09M	513.61M	656.27M	291.28M
Stockholders Equity	729.11M	2.14B	729.11M	353.67M	855.17M	3.08B
Cash Flow
Free Cash Flow	0	-984.97M	-815.30M	-1.23B	-800.29M	-1.81B
Operating Cash Flow	0	-922.75M	-815.02M	-1.23B	-794.90M	-1.76B
Investing Cash Flow	0	-63.22M	-279.00K	-33.35M	-20.32M	-52.23M
Financing Cash Flow	0	2.24B	1.12B	671.37M	95.95M	0

OncoTherapy Science Technical Analysis

Technical Analysis SentimentNegative

Last Price17.00

Price Trends

50DMA20.20Negative

100DMA19.94Negative

200DMA21.00Negative

Market Momentum

MACD-0.88Positive

RSI37.85Neutral

STOCH27.78Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4564, the sentiment is Negative. The current price of 17.00 is below the 20-day moving average (MA) of 18.25, below the 50-day MA of 20.20, and below the 200-day MA of 21.00, indicating a bearish trend. The MACD of -0.88 indicates Positive momentum. The RSI at 37.85 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4564.

OncoTherapy Science Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

JP:4564 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:4565	63Neutral	JPY 146.80B	-28.89	-8.51%	―	23.72%	12.48%
JP:4579	60Neutral	JPY 16.09B	67.37	―	―	20.64%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JP:4588	51Neutral	JPY 233.66B	-144.29	―	―	1662.38%	42.86%
JP:4564	42Neutral	JPY 6.94B	-7.20	-42.79%	―	-8.58%	19.03%
JP:4571	42Neutral	JPY 7.01B	-5.80	-33.61%	―	74.24%	-7.78%
JP:4587	42Neutral	JPY 145.28B	-40.98	-7.17%	―	0.62%	27.66%

* Healthcare Sector Average

Performance Comparison

JP:4564 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:4564	OncoTherapy Science, Inc.	17.00	-7.00	-29.17%
JP:4587	Peptidream	1106.00	-419.50	-27.50%
JP:4565	Sosei Group Corporation	1520.00	739.00	94.62%
JP:4571	NanoCarrier Co., Ltd.	78.00	-80.00	-50.63%
JP:4579	RaQualia Pharma Inc.	590.00	101.00	20.65%
JP:4588	Oncolys BioPharma, Inc.	8300.00	7449.00	875.32%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 11, 2026

OncoTherapy Science AI Stock Analysis